A broad-spectrum immune support stack combining thymosin alpha-1's T-cell maturation and adaptive immune enhancement with LL-37's antimicrobial peptide activity and innate immune modulation. Thymosin alpha-1 is clinically used to restore immune competence in immunocompromised patients by promoting dendritic cell and NK cell activity, while LL-37 provides direct antimicrobial action and regulates inflammatory signalling. The stack targets both adaptive and innate arms of immunity through complementary mechanisms.